心脏移植后前列腺癌：单中心病例对照研究。

Prostate cancer after heart transplantation: unicenter case-control study.

作者信息

Mohammadi Siamak, Silvaggio Giuseppe, Bonnet Nicolas, Berberian George, Dorent Richard, Bikter Marc, Pavie Alain, Gandjbakhch Iradj

机构信息

Institute of Cardiology, Thoracic and Cardiovascular Surgery Department, La Pitié Hospital, Paris, France.

出版信息

J Heart Lung Transplant. 2005 Aug;24(8):995-7. doi: 10.1016/j.healun.2004.06.020.

DOI:10.1016/j.healun.2004.06.020

PMID:16102432

Abstract

BACKGROUND

We have noted an unexpectedly high incidence of prostate cancer in our heart transplant recipients (HTR).

METHODS

We conducted a retrospective review of patients after heart transplantation to investigate the prevalence, treatment, and outcome of prostate cancer diagnosed after systematic screening (study group). We compared them with case-matched HTR (control).

RESULTS

Among 702 recipients, 15 patients had elevated prostate-specific antigen (PSA) levels. Fourteen cases of prostate cancer were diagnosed and treated. The median time between transplantation and prostate cancer diagnosis was 73 months. No patient was diagnosed in a locally advanced (>T2) or metastatic stage. Eleven patients (78.6%) received curative treatment. During follow-up (median, 44 months), 1 patient died from prostate cancer. The survival rate between the study and control groups did not differ.

CONCLUSION

Routine PSA testing is recommended as a screening test for prostate cancer in patients after heart transplantation. We believe this could also result in detection of early stages of prostate cancer, thus allowing curative treatment, and achieving similar survival to other case-matched HTR with no prostate cancer.

摘要

背景

我们注意到心脏移植受者（HTR）中前列腺癌的发病率意外地高。

方法

我们对心脏移植后的患者进行了回顾性研究，以调查经系统筛查后诊断出的前列腺癌的患病率、治疗方法和结果（研究组）。我们将他们与病例匹配的心脏移植受者（对照组）进行了比较。

结果

在702名受者中，15名患者的前列腺特异性抗原（PSA）水平升高。诊断并治疗了14例前列腺癌。移植与前列腺癌诊断之间的中位时间为73个月。没有患者被诊断为局部晚期（>T2）或转移阶段。11名患者（78.6%）接受了根治性治疗。在随访期间（中位时间为44个月），1名患者死于前列腺癌。研究组和对照组之间的生存率没有差异。